Aptinyx Inc reported $0 in Sales Revenues for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Acadia Pharmaceuticals ACAD:US $ 115.47M 15.29M
Acorda Therapeutics ACOR:US $ 22.53M 14.43M
Biogen BIIB:US $ 2531.8M 202M
Cara Therapeutics CARA:US $ 4.79M 3.97M
Daiichi Sankyo 4568:JP Y 233925M 47076M
Eli Lilly And LLY:US $ 7810M 189.9M
Halozyme Therapeutics HALO:US $ 117.28M 15.28M
Intra Cellular Therapies ITCI:US $ 35M 9.32M
IONIS PHARMACEUT IONS:US $ 141.92M 298.09M
Marinus Pharmaceuticals MRNS:US 14.19M 12.67M
Neurocrine Biosciences NBIX:US $ 310.6M 1.4M
Novartis NOVN:VX SF 12814M 708M
Ultragenyx Pharmaceutical RARE:US $ 79.94M 3.45M
Vertex Pharmaceuticals VRTX:US $ 2097.5M 24.94M